QuantaMatrix

QuantaMatrix AAQS

The The AAQS of QuantaMatrix (317690.KQ) as of Oct 27, 2026 is 2. In the previous year, The AAQS was 2.00 — a change of 0.00% (lower).

AAQS

2

YoY

0.00%

Last updated:

QuantaMatrix has a current AAQS of 2.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock QuantaMatrix in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The QuantaMatrix AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2018
2.00 KRW
Jan 1, 2019
2.00 KRW
Jan 1, 2020
2.00 KRW
Jan 1, 2021
2.00 KRW
Jan 1, 2022
2.00 KRW
Jan 1, 2023
2.00 KRW
Jan 1, 2024
2.00 KRW
Jan 1, 2025
2.00 KRW
The QuantaMatrix AAQS history
YEARAAQSYoY
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
2—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

QuantaMatrix Stock analysis

What does QuantaMatrix do? QuantaMatrix Inc. generates revenue through the sale of its multi-diagnostic unique test platform, micro disc, antimicrobial susceptibility testing sepsis diagnostic equipment, molecular immunity diagnosis automation platform, rapid antituberculosis susceptibility testing equipment, and rapid antituberculosis susceptibility testing kits. The company also sells covid kits and conducts research and development for microbial diagnostic products. Its primary customers include healthcare facilities and laboratories requiring advanced diagnostic solutions for microbiological and molecular testing. The firm targets segments focused on infectious disease diagnostics, antimicrobial resistance testing, and rapid tuberculosis detection. The company's product portfolio emphasizes innovative diagnostic tools, with a strong focus on sepsis diagnostics and tuberculosis testing. By offering both equipment and kits, QuantaMatrix addresses diverse needs within the healthcare sector. The firm's research and development activities support continuous product enhancement and expansion into new diagnostic areas. QuantaMatrix Inc. serves the global market for diagnostic equipment, with particular emphasis on regions where infectious disease management is critical. Its products are designed to meet the demands of healthcare providers seeking efficient, accurate, and rapid diagnostic solutions. The company's strategy centers on leveraging its technological expertise to capture market share in specialized diagnostic segments. QuantaMatrix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about QuantaMatrix stock

The AAQS of QuantaMatrix is 2 in 2025.

On Eulerpool you can find the complete historical development of The AAQS QuantaMatrix since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — QuantaMatrix

All Key Metrics — QuantaMatrix